Survival trends in Hypopharyngeal cancer: A population-based review

Newman, J. Robert; Connolly, Timothy M.; Illing, Elisa A.; Kilgore, Meredith L.; Locher, Julie L.; Carroll, William R.

doi:10.1002/lary.24915

Cited by 199 publications

(175 citation statements)

References 27 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…Also, hypopharynx is rich in highly anastomotic regional lymph vessel, leading to early dissemination. A United States (US) study [37], showed a survival improvement for patients with hypopharyngeal cancer, since the beginning of the nineties. Treatment of these patients has been increasingly given with some form of radiotherapy, and the majority of patients were treated non-surgically.…”

Section: Discussionmentioning

confidence: 99%

Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study

Anderson

Licitra

Hackl

et al. 2015

European Journal of Cancer

368

287

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study

Anderson

Licitra

Hackl

et al. 2015

European Journal of Cancer

368

287

View full text Add to dashboard Cite

“…It was reported that there were an estimated 387,100 new cases of HNC and 196,200 deaths in 2012 worldwide [1]. Despite the development in diagnosis and treatment, the survival of patients with HNC is still not significantly improved, with 5-year survival rate approximately 40%–50% [2, 3]. Therefore, it is necessary to explore strategies to screen out high risk patients and predict outcome of this disease.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis

et al. 2016

View full text Add to dashboard Cite

Several studies have assessed the clinicopathological and prognostic value of cyclooxygenase-2 (COX-2) expression in patients with head and neck cancer (HNC), but their results remain controversial. To address this issue, a meta-analysis was carried out. A total of 29 studies involving 2430 patients were subjected to final analysis. Our results indicated that COX-2 expression was not statistically associated with advanced tumor stage (OR, 1.23; 95% CI, 0.98–1.55) but correlated with high risk of lymph node metastasis (OR, 1.28; 95% CI, 1.03–1.60) and advanced TNM stage (OR, 1.33; 95% CI, 1.06–1.66). Moreover, COX-2 expression had significant effect on poor OS (HR, 1.93; 95% CI, 1.29–2.90), RFS (HR, 2.02; 95% CI, 1.00–4.08) and DFS (HR, 5.14; 95% CI, 2.84–9.31). The results of subgroup analyses revealed that COX-2 expression was related with high possibility of lymph node metastasis in oral cancer (OR, 1.49; 95% CI, 1.01–2.20) and advanced TNM stage in oral cancer (OR, 1.58; 95% CI, 1.05–2.37) and no site-specific HNC (OR, 1.64; 95% CI, 1.02–2.62). However, subgroup analyses only showed a tendency without statistically significant association between COX-2 expression and survival. Significant heterogeneity was not found when analyzing clinicopathological data, but it appeared when considering survival data. No publication bias was detected in this study. This meta-analysis suggested that COX-2 expression could act as a prognostic factor for patients with HNC.

show abstract

“…9 Alternatively, these patients may be treated with partial laryngopharyngectomy, either open or endoscopic, with neck dissection. These patients may be treated with primary radiotherapy in a variety of fractionation options with surgical salvage in cases of incomplete response.…”

Section: Guidelines In Early Stage Diseasementioning

confidence: 99%

Hypopharyngeal carcinoma: Do you know your guidelines?

Kwon

Miles

2018

Head & Neck

View full text Add to dashboard Cite

Background Hypopharyngeal carcinoma is relatively rare, representing approximately 3% of all head and neck malignancies. It also is characterized by having one of the worst prognoses at time of diagnosis. This is largely due to its tendency for late presentation. Methods This article will review current literature including as well as the National Comprehensive NCCN Guidelines Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of hypopharyngeal cancer. Results Hypopharyngeal cancer often presents in an advanced stage and its prognosis is notoriously poor. Treatment goals are similar to other carcinomas of the head and neck and treatment typically involves multiple modalities including surgery, radiation, and chemotherapy. Organ sparing nonsurgical therapy has shown comparable survival outcomes to surgery in early stage hypopharyngeal cancer. Conclusion Treating hypopharyngeal cancer remains a challenging prospect for the head and neck oncologist. A multidisciplinary approach is essential due to the necessity of combined therapy treatment protocols. There is opportunity for novel treatments and prospective trials to improve outcomes in hypopharyngeal carcinoma. Disease prevention by targeting environmental risk factors is likely to have the greatest impact in this disease.

show abstract

Survival trends in Hypopharyngeal cancer: A population-based review

Abstract: There has been a trend away from surgical therapy for hypopharyngeal SCC. In contrast to laryngeal cancer, survival for hypopharyngeal cancer has improved since 1990.

Cited by 199 publications

References 27 publications

Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study

Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study

Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis

Hypopharyngeal carcinoma: Do you know your guidelines?

Contact Info

Product

Resources

About